These findings provide mechanistic evidence that bilirubin or altered bilirubin metabolism (e.g., partial UGT1A1 inhibitors49) may be useful as a therapeutic approach to reduce obesity and improve insulin resistance and glucose tolerance. Here, UGT1A1 is linked to Obesity.